BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pharm-Olam International Ltd. Completes Phase 3 Ophthalmology Study


4/25/2013 11:44:16 AM

Houston, TX (PRWEB) April 24, 2013 -- Pharm-Olam International, a multinational full-service Contract Research Organization (CRO) to the pharmaceutical and biotech industries, announced the successful completion of a Phase 3 ophthalmology study in conjunction with InSite Vision.

As the CRO for InSite Vision, Pharm-Olam managed the Phase 3 clinical study to verify the efficacy of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. The study included the enrollment and management of 268 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite. Patients were randomized and then dosed twice a day beginning the day before surgery and continuing the day of surgery and for 14 days post-surgery. The primary study endpoint was the reduction of inflammation after surgery.

Cataract surgery is the most frequently performed ocular surgery in the United States, with more than three million procedures occurring annually. Typically, anti-inflammatory eye drops are prescribed to reduce pain and inflammation both before and after surgery.

John Hovre, Chief Operating Officer at Pharm-Olam commented, “Our client, InSite Vision, was very pleased with the positive results of the BromSite™ study. We wish InSite Vision the best in their continued study efforts and we look forward to working with them on future projects in the ophthalmic space.”

For further information about Pharm-Olam, please visit http://www.pharm-olam.com.

About Pharm-Olam International

Pharm-Olam International is a multinational contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.

About InSite Vision

InSite Vision is advancing new ophthalmic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2® drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

For further information on InSite Vision, please visit http://www.insitevision.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES